MTOR and nonpapillary renal cell carcinoma: In conclusion, classifying CCRCC according to VHL/VEGF status could potentially help physicians to choose the appropriate therapeutic strategy according to the molecular stage of the disease: surgery/immunotherapy, surgery/TKIs and mTOR inhibitors.